EMA Recommends 39 Drugs in First Half of 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Recommends 39 Drugs in First Half of 2014


Thirty-nine drugs were recommended for marketing authorization by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in the first half of 2014, compared with 44 in first half of 2013 and 33 in first half of 2012. The recommended drugs included drugs designed to fill unmet medical needs, treat diseases for which no treatments were previously available, or bring significant added benefit to patients over existing therapies. The number of new medicines intended for the treatment of rare diseases increased, with eight drugs recommended for the treatment of rare diseases in the first half of 2014. The number of drug products recommended for approval via the European Union centralized procedure based on generic or informed consent applications, however, has decreased compared with the first half of 2013 (6 versus 13). 

More than two in three applicants received scientific advice from the CHMP during the development phase, and for innovative medicines, four in five applicants received such advice, a significant increase compared with the first half of 2013. This trend is in line with the growing number of requests for scientific advice received by EMA.

Source: European Medicines Agency

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here